Impact of anemia correction on the production of the circulating morphogenetic protein α-Klotho in patients with Stages 3B—4 chronic kidney disease: A new direction of cardionephroprotection
Aim. To investigate the impact of anemia correction with erythropoiesis stimulants on the serum level of the circulating morphogenetic protein α-Klotho in patients with Stages 3B—4 chronic kidney disease (CKD). Subjects and methods. 64 patients aged 42±8 years with Stages 3B—4 nondiabetic CKD were e...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
"Consilium Medicum" Publishing house
2016-06-01
|
| Series: | Терапевтический архив |
| Subjects: | |
| Online Access: | https://ter-arkhiv.ru/0040-3660/article/viewFile/31977/pdf |
| _version_ | 1811288711176912896 |
|---|---|
| author | Yu S Milovanov N A Mukhin L V Kozlovskaya S Yu Milovanova M M Markina |
| author_facet | Yu S Milovanov N A Mukhin L V Kozlovskaya S Yu Milovanova M M Markina |
| author_sort | Yu S Milovanov |
| collection | DOAJ |
| description | Aim. To investigate the impact of anemia correction with erythropoiesis stimulants on the serum level of the circulating morphogenetic protein α-Klotho in patients with Stages 3B—4 chronic kidney disease (CKD). Subjects and methods. 64 patients aged 42±8 years with Stages 3B—4 nondiabetic CKD were examined and divided into 2 groups: 1) 32 patients with anemia (the target hemoglobin levels could be achieved and kept with erythropoietin and iron saccharate in 20 patients (Group A) and those could not be done in 12 patients (Group 1B). A control group (Group 2) consisted of 32 non-anemic patients matched for gender, age, and degree of a glomerular filtration rate (GFR) reduction. Along with iron exchange indicators, the time course of changes in serum Klotho levels were examined in all the 64 patients during screening and one year after the end of the study. For correction of anemia, 32 patients with this condition (Groups 1A and 1B) took short-acting epoetin (hypodermic recormon 2,000 IU thrice per week + iron (intravenous venofer 5 ml of 100 mg once per week)) under control of hemoglobin levels and serum transferrin iron and ferritin saturation. After achieving the target hemoglobin level of 110-120 g/l, for its keeping, all the patients received, instead of short-acting epoetin, long-acting hypodermic darbepoetin-α 1.5 µg once every 2 months and intravenous iron saccharate 100 mg once every 2 weeks. Results. Among the 32 anemic patients in Group 1, 20 (63%) (Group 1 A) could achieve the target hemoglobin level (110—120 g/l) and maintain it within this range, by performing therapy with epoitin-β + iron saccharate; anemia (the hemoglobin level of |
| first_indexed | 2024-04-13T03:41:35Z |
| format | Article |
| id | doaj.art-ae868a7ea71d4d8ea41fa2662927e7b2 |
| institution | Directory Open Access Journal |
| issn | 0040-3660 2309-5342 |
| language | Russian |
| last_indexed | 2024-04-13T03:41:35Z |
| publishDate | 2016-06-01 |
| publisher | "Consilium Medicum" Publishing house |
| record_format | Article |
| series | Терапевтический архив |
| spelling | doaj.art-ae868a7ea71d4d8ea41fa2662927e7b22022-12-22T03:04:07Zrus"Consilium Medicum" Publishing houseТерапевтический архив0040-36602309-53422016-06-01886212528993Impact of anemia correction on the production of the circulating morphogenetic protein α-Klotho in patients with Stages 3B—4 chronic kidney disease: A new direction of cardionephroprotectionYu S MilovanovN A MukhinL V KozlovskayaS Yu MilovanovaM M MarkinaAim. To investigate the impact of anemia correction with erythropoiesis stimulants on the serum level of the circulating morphogenetic protein α-Klotho in patients with Stages 3B—4 chronic kidney disease (CKD). Subjects and methods. 64 patients aged 42±8 years with Stages 3B—4 nondiabetic CKD were examined and divided into 2 groups: 1) 32 patients with anemia (the target hemoglobin levels could be achieved and kept with erythropoietin and iron saccharate in 20 patients (Group A) and those could not be done in 12 patients (Group 1B). A control group (Group 2) consisted of 32 non-anemic patients matched for gender, age, and degree of a glomerular filtration rate (GFR) reduction. Along with iron exchange indicators, the time course of changes in serum Klotho levels were examined in all the 64 patients during screening and one year after the end of the study. For correction of anemia, 32 patients with this condition (Groups 1A and 1B) took short-acting epoetin (hypodermic recormon 2,000 IU thrice per week + iron (intravenous venofer 5 ml of 100 mg once per week)) under control of hemoglobin levels and serum transferrin iron and ferritin saturation. After achieving the target hemoglobin level of 110-120 g/l, for its keeping, all the patients received, instead of short-acting epoetin, long-acting hypodermic darbepoetin-α 1.5 µg once every 2 months and intravenous iron saccharate 100 mg once every 2 weeks. Results. Among the 32 anemic patients in Group 1, 20 (63%) (Group 1 A) could achieve the target hemoglobin level (110—120 g/l) and maintain it within this range, by performing therapy with epoitin-β + iron saccharate; anemia (the hemoglobin level ofhttps://ter-arkhiv.ru/0040-3660/article/viewFile/31977/pdfchronic kidney diseaseanemiaerythropoiesis stimulantscirculating α-klotho |
| spellingShingle | Yu S Milovanov N A Mukhin L V Kozlovskaya S Yu Milovanova M M Markina Impact of anemia correction on the production of the circulating morphogenetic protein α-Klotho in patients with Stages 3B—4 chronic kidney disease: A new direction of cardionephroprotection Терапевтический архив chronic kidney disease anemia erythropoiesis stimulants circulating α-klotho |
| title | Impact of anemia correction on the production of the circulating morphogenetic protein α-Klotho in patients with Stages 3B—4 chronic kidney disease: A new direction of cardionephroprotection |
| title_full | Impact of anemia correction on the production of the circulating morphogenetic protein α-Klotho in patients with Stages 3B—4 chronic kidney disease: A new direction of cardionephroprotection |
| title_fullStr | Impact of anemia correction on the production of the circulating morphogenetic protein α-Klotho in patients with Stages 3B—4 chronic kidney disease: A new direction of cardionephroprotection |
| title_full_unstemmed | Impact of anemia correction on the production of the circulating morphogenetic protein α-Klotho in patients with Stages 3B—4 chronic kidney disease: A new direction of cardionephroprotection |
| title_short | Impact of anemia correction on the production of the circulating morphogenetic protein α-Klotho in patients with Stages 3B—4 chronic kidney disease: A new direction of cardionephroprotection |
| title_sort | impact of anemia correction on the production of the circulating morphogenetic protein α klotho in patients with stages 3b 4 chronic kidney disease a new direction of cardionephroprotection |
| topic | chronic kidney disease anemia erythropoiesis stimulants circulating α-klotho |
| url | https://ter-arkhiv.ru/0040-3660/article/viewFile/31977/pdf |
| work_keys_str_mv | AT yusmilovanov impactofanemiacorrectionontheproductionofthecirculatingmorphogeneticproteinaklothoinpatientswithstages3b4chronickidneydiseaseanewdirectionofcardionephroprotection AT namukhin impactofanemiacorrectionontheproductionofthecirculatingmorphogeneticproteinaklothoinpatientswithstages3b4chronickidneydiseaseanewdirectionofcardionephroprotection AT lvkozlovskaya impactofanemiacorrectionontheproductionofthecirculatingmorphogeneticproteinaklothoinpatientswithstages3b4chronickidneydiseaseanewdirectionofcardionephroprotection AT syumilovanova impactofanemiacorrectionontheproductionofthecirculatingmorphogeneticproteinaklothoinpatientswithstages3b4chronickidneydiseaseanewdirectionofcardionephroprotection AT mmmarkina impactofanemiacorrectionontheproductionofthecirculatingmorphogeneticproteinaklothoinpatientswithstages3b4chronickidneydiseaseanewdirectionofcardionephroprotection |